The Ministry of Food and Drug Safety said it will crack down on drug safety information as well as hype activities for the ...

The US Food and Drug Administration (FDA) has granted approval for Ascendis Pharma’s Skytrofa (lonapegsomatropin-tcgd, developed as TransCon hGH), a prodrug of somatropin or human growth hormone (HGH) ...

Lonapegsomatropin is a pegylated prodrug of the human growth hormone, somatropin, administered as a subcutaneous injection once-weekly.

The hypothalamus regulates growth hormone secretion through two opposing mechanisms: growth hormone-releasing hormone (GHRH) stimulates release, while somatostatin inhibits it.

Patients with acromegaly, a rare disorder caused by excessive growth hormone secretion, may face a higher risk for various cancers at younger ages.

The pituitary gland regulates growth, metabolism, and reproduction through hormone secretion. When the gland does not produce enough growth hormone (GH), a deficiency occurs, usually resulting in ...

Growth Hormone Secretion After Conformal Radiation Therapy in Pediatric Patients With Localized Brain Tumors. JCO 29, 4776-4780(2011).

Pediatrics > Growth Disorders Once-Weekly Pediatric Growth Hormone Snags FDA Approval — Somatrogon injection given go-ahead after initial FDA rejection last year by Maja Clasen, MedPage Today ...

The FDA has approved Skytrofa® (lonapegsomatropin-tcgd) to treat patients 1 year of age and older weighing at least 11.5kg and have a growth failure due to inadequate secretion of endogenous ...

The recommended dose of SKYTROFA for treatment-naïve children with growth hormone deficiency and those switching from daily somatropin is 0.24 mg/kg body weight, administered once weekly. [2] ...